FIELD NOTE
The First Robot Licensed to Stick You.
The FDA did something on Tuesday that it has never done before: it authorized a machine to perform venipuncture on its own.
The device is the Aletta, built by Utrecht-based Vitestro, and the agency granted it marketing authorization through the De Novo pathway as the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention. A patient places their arm in the machine. The Aletta scans with near-infrared light and Doppler ultrasound to find a vein — and to confirm it isn’t an artery — then applies the tourniquet, preps the skin, inserts the needle, swaps collection tubes, and places the bandage. If it can’t find a suitable vein, it declines to try. If the patient moves too much, the needle detaches automatically and the draw stops.
A trained phlebotomist still initiates each session and supervises throughout. But here is the number that matters: one phlebotomist can oversee up to three Aletta devices at once. That ratio is the entire commercial thesis. Blood draws are among the most commonly performed procedures in American medicine, the phlebotomist shortage is real and worsening, and Vitestro is not selling a robot so much as selling a 3-to-1 conversion on scarce labor.
What should hold the attention of anyone who builds devices is how the FDA cleared it. The agency’s authorization rests on clinical data showing the Aletta achieves successful draw rates comparable to or better than trained human phlebotomists when it proceeds with a stick — demonstrated across patients with varying health statuses, self-reported difficult vein access, and varying skin tones. In pivotal testing, the device posted a 94.5% first-stick success rate, and 90% of patients reported pain equal to or less than a manual draw. The regulatory benchmark for an autonomous device, in other words, was the human it replaces. Expect that comparator design to become the template for every autonomous-care submission that follows.
The second structural detail is buried in the authorization itself. Alongside the De Novo, the FDA established special controls — labeling, performance, and clinical testing requirements that define a brand-new device category. Once those controls exist, competitors don’t need their own De Novo. They can reach the U.S. market through the 510(k) pathway, citing Aletta as the predicate class. Vitestro spent years and considerable capital being first; the reward is roughly a product cycle of runway before the door it opened admits everyone else. That is the standing bargain of the De Novo pathway, and this is as clean an example as the industry gets.
Vitestro appears to have priced that bargain in. The company raised $70 million in March expressly to fund the U.S. entry — a Series B whose investors include Labcorp Venture Fund, Mayo Clinic, and Sutter Health. Read that list again: a national reference lab and two major health systems, all of whom operate exactly the high-volume outpatient draw sites Vitestro says it will target first. The cap table is the distribution plan. The Aletta earned its CE mark in August 2024 and has been running in European hospitals since — meaning the U.S. launch arrives with operational evidence, not just trial data.
The Aletta will not take blood from your toughest stick, and it isn’t going into inpatient units yet — the authorization covers adults in outpatient settings, under supervision. But the categorical line it crossed doesn’t get uncrossed. The FDA has now written rules for machines that perform invasive procedures on their own, and it graded the first one against people.
SPONSORED BY RŌG HEALTH
Most device companies don't fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.